In the TRG1 subgroup, the YKL-40 tumor expression ranged from 0 to 30% (mean: 7.7; median: 0), and that of c-Met ranged from 0 to 50% (mean: 12.5; median: 0); specifically YKL-40 and c-Met immunoreaction was absent in 67% and 62% of TRG1 cases, respectively. The gene discussed is CHI3L1; the disease is neoplasm.